Latest Psoriasis Stories
ST. LOUIS, Oct.
Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct.
FLINT, Mich., Oct.
Be Joint Smart to educate roughly 35,000 local residents with PsA about their disease PORTLAND, Ore., Sept.
Be Joint Smart to educate roughly 150,000 local residents with PsA about their disease PORTLAND, Ore., Sept.
Independent, 3rd party scientists review psoriasis treatments and the benefits of small molecule drugs including CF101; PETACH TIKVA, Israel, Sept.
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark,
Lexington Int’l is pleased to announce the publication of the results of a clinical review with the HairMax LaserComb in a peer-review medical journal, validating efficacy for treating hereditary
TNF-Alpha Inhibitors--Including Sales Leader Humira--Accounted for Over 90 Percent of the Psoriatic Arthritis Market, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Newly Acquired SGX301 Orphan Drug Candidate Being Evaluated for Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 5, 2014 /PRNewswire/ -- Soligenix, Inc.
- Large; stout; burly.